Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

7.7%

1 terminated/withdrawn out of 13 trials

Success Rate

88.9%

+2.4% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

100%

8 of 8 completed trials have results

Key Signals

4 recruiting8 with results

Enrollment Performance

Analytics

Early Phase 1

9(69.2%)

N/A

3(23.1%)

Phase 1

1(7.7%)

13Total

Early Phase 1(9)

N/A(3)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (13)

Showing 13 of 13 trials

NCT05610072Early Phase 1Completed

Behavioral Effects of Drugs (Inpatient): 43 (Opioids, Cocaine, n-Acetylcysteine)

Role: lead

NCT07226596Not ApplicableRecruiting

Non-Abstinence Outcomes in Methamphetamine Use Disorder

Role: lead

NCT06989853Early Phase 1Recruiting

Methamphetamine and Troriluzole

Role: lead

NCT06326684Early Phase 1Recruiting

Suvorexant and Alcohol

Role: lead

NCT07086794Early Phase 1Recruiting

Cocaine and Pentoxifylline (BED IN 47)

Role: lead

NCT05019430Early Phase 1Completed

Cocaine and Zolmitriptan

Role: lead

NCT03224546Not ApplicableCompleted

Cocaine Use Reduction and Health

Role: lead

NCT03954938Early Phase 1Terminated

Behavioral Effects of Drugs (Inpatient): 38

Role: lead

NCT03937986Early Phase 1Completed

Suvorexant and Cocaine

Role: lead

NCT03216954Early Phase 1Completed

Influence of n-Acetylcysteine Maintenance on Alcohol Effects

Role: lead

NCT02522325Phase 1Completed

Reinforcing Effects of Cocaine During Phendimetrazine Maintenance

Role: lead

NCT02233647Early Phase 1Completed

Phendimetrazine and Cocaine

Role: lead

NCT01639157Not ApplicableCompleted

Impact of Buspirone Maintenance on the Reinforcing Effects of Cocaine

Role: lead

All 13 trials loaded